November 20, 2014 - Changes in the lipid layer of the eyes' natural tear film may contribute to the common problem of contact lens discomfort, reports a study in the December issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Applying a liposomal eyelid spray appears to reduce drying of the tear film and help make wearing contact lenses more comfortable, according to the pilot study by Fiona Stapleton, PhD, FAAO, of University of New South Wales, Sydney, and colleagues.
Contact Lenses Alter Lipid Layer of Tear Film...
The researchers performed in-depth analyses of the tear film in two groups of soft contact lens wearers: ten with contact lens discomfort and ten without discomfort. The tear film is a three-layered "sandwich" of fluids that nourish and protects the eyes.
The study focused on the tear film's outermost layer, which is composed of fat- and wax-like molecules called lipids. The lipid layer performs an important barrier function in preventing evaporation of tears and maintaining stability of the tear film.
The researchers found some differences in the tear film of patients with and without contact lens discomfort. In particular, patients with discomfort showed degradation of the lipid layer after a few hours of wearing contact lenses.
A measure of drying of the surface of the eye also differed between groups. Time for the first dry spot to appear on the eye surface after blinking was less than half as long in patients with contact lens discomfort: 4.5 seconds, compared to 9.9 seconds in patients without discomfort.
...With Possible Benefit of a Liposomal Eyelid Spray
Dr Stapleton and colleagues also evaluated the effects of a liposomal spray designed to protect the tear film. After the liposomal product was sprayed on the eyelids, the stability of the tear film increased significantly. There were also increased levels of a specific enzyme (phospholipase) affecting lipid metabolism.
For the patients with contact lens discomfort, drying times were significantly longer after using the liposomal eyelid spray. Contact lens comfort was increased for up to six hours after using the liposomal spray, compared to an inactive solution.
Contact lens discomfort is a very common problem. Previous studies have suggested that the tear film plays an important role in contact lens discomfort. The liposomal eyelid spray used in the study has shown benefits in patients who have problems with dry eyes.
The new study, using detailed, laboratory-based methods, adds new evidence that the lipid layer is degraded in patients with contact lens discomfort. It also suggests that the liposomal eyelid spray can improve tear film stability and certain components of the lipid layer--potentially improving problems with contact lens discomfort.
"Discomfort is the primary reason why otherwise successful contact lens wearers don't wear contact lenses," comments Anthony Adams, OD, PhD, Editor-in-Chief of Optometry and Vision Science. "Our authors identify the changes in the lipid layer of the tear film in people who have discomfort wearing contact lenses. They also provide preliminary evidence that a lipid supplement spray can help keep the eyes from drying and provide improvement in contact lens comfort."
About Optometry and Vision Science
Optometry and Vision Science, official journal of the American Academy of Optometry, is the most authoritative source for current developments in optometry, physiological optics, and vision science. This frequently cited monthly scientific journal has served primary eye care practitioners for more than 75 years, promoting vital interdisciplinary exchange among optometrists and vision scientists worldwide.
About the American Academy of Optometry
Founded in 1922, the American Academy of Optometry is committed to promoting the art and science of vision care through lifelong learning. All members of the Academy are dedicated to the highest standards of optometric practice through clinical care, education or research.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health's market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America.maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Follow our official Twitter handle: @WKHealth.